A detailed history of Strategic Blueprint, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Strategic Blueprint, LLC holds 960 shares of VRTX stock, worth $462,614. This represents 0.03% of its overall portfolio holdings.

Number of Shares
960
Previous 656 46.34%
Holding current value
$462,614
Previous $266,000 50.75%
% of portfolio
0.03%
Previous 0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$407.69 - $446.08 $123,937 - $135,608
304 Added 46.34%
960 $401,000
Q4 2023

Jan 25, 2024

BUY
$343.0 - $410.68 $225,008 - $269,406
656 New
656 $266,000
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $10,702 - $11,976
-59 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $11,061 - $13,044
59 New
59 $11,000
Q4 2020

Jan 26, 2021

SELL
$207.01 - $276.09 $264,558 - $352,843
-1,278 Closed
0 $0
Q3 2020

Oct 27, 2020

BUY
$255.65 - $303.1 $326,720 - $387,361
1,278 New
1,278 $348,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $124B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Strategic Blueprint, LLC Portfolio

Follow Strategic Blueprint, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Blueprint, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Blueprint, LLC with notifications on news.